SEC Company Response from ADIAL PHARMACEUTICALS, INC. (ADIL) (CIK 0001513525) (AZR) — Jul 24, 2018
ADIAL PHARMACEUTICALS, INC. (ADIL) (CIK 0001513525)
Date: July 24, 2018 · CIK: 0001513525 · Accession: 0001213900-18-009576
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-220368
Letter
VIA EDGAR Division of Corporation Finance SECURITIES AND EXCHANGE COMMISSION Attention: Joseph McCann, Staff Attorney Re: Adial Pharmaceuticals, Inc. Registration Statement on Form S-1; (SEC File No. 333-220368)
Dear Mr. McCann:
Acting as representative to the several underwriters, we hereby join in the request of Adial Pharmaceuticals, Inc. that the effective date of the above-captioned Registration Statement be accelerated so that it will become effective at 5:00 p.m., Eastern Time, on July 26, 2018, or as soon thereafter as practicable.
Pursuant to Rule 460 of the General Rules and Regulations of the Securities and Exchange Commission under the Securities Act of 1933, as amended, we, acting on behalf of the several underwriters, wish to advise you that, between July 10, 2018 and July 24, 2018, we distributed to each underwriter or dealer, who is reasonably anticipated to be invited to participate in the distribution of the security “E-red” copies of the Preliminary Prospectus dated July 10, 2018 as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
We confirm that we are aware of our obligations under the Securities Act of 1933, as amended, and that we have and will comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, with respect to the distribution of Prospectus. We have been informed by the other underwriters participating in the distribution of this offering that such persons have and will comply with Rule 15c2-8 with respect to the distribution of Prospectus.
Very Truly Yours,
By:
JOSEPH GUNNAR & CO., LLC
Show Raw Text
CORRESP
1
filename1.htm
JOSEPH
GUNNAR & CO., LLC
30 Broad Street, 11th Floor
New York, New York 10004
July 24, 2018
VIA EDGAR
Division of Corporation Finance
SECURITIES AND EXCHANGE COMMISSION
100 F Street, N.E.
Washington, DC 20549
Attention: Joseph McCann, Staff Attorney
Re: Adial Pharmaceuticals, Inc.
Registration Statement on Form
S-1;
(SEC File No. 333-220368)
Dear Mr. McCann:
Acting as representative
to the several underwriters, we hereby join in the request of Adial Pharmaceuticals, Inc. that the effective date of the above-captioned
Registration Statement be accelerated so that it will become effective at 5:00 p.m., Eastern Time, on July 26, 2018, or as soon
thereafter as practicable.
Pursuant to Rule 460
of the General Rules and Regulations of the Securities and Exchange Commission under the Securities Act of 1933, as amended, we,
acting on behalf of the several underwriters, wish to advise you that, between July 10, 2018 and July 24, 2018, we distributed
to each underwriter or dealer, who is reasonably anticipated to be invited to participate in the distribution of the security “E-red”
copies of the Preliminary Prospectus dated July 10, 2018 as appears to be reasonable to secure adequate distribution of the preliminary
prospectus.
We confirm that we
are aware of our obligations under the Securities Act of 1933, as amended, and that we have and will comply with Rule 15c2-8 under
the Securities Exchange Act of 1934, as amended, with respect to the distribution of Prospectus. We have been informed by the other
underwriters participating in the distribution of this offering that such persons have and will comply with Rule 15c2-8 with respect
to the distribution of Prospectus.
Very Truly Yours,
By:
JOSEPH GUNNAR & CO., LLC
By:
/s/ Stephan Stein
Name:
Stephan Stein
Title:
President